Novel chemotherapeutic approaches to brain tumors

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

In reviewing the numerous investigational drug trials for patients with anaplastic gliomas over the past 20 years, it would be fair to say that there have been more than a few disappointments and that the real impact of many of these therapies on patients' duration and quality of survival has been minor at best. It is also fair to state that there has been progress in developing new types of chemotherapy and other agents, in devising new treatment strategies, and in gaining a deeper understanding of the problems that must be overcome to treat patients with anaplastic gliomas successfully. The past several years have seen the realization that oligodendroglioma, primary CNS lymphoma, and medulloblastoma are sensitive to chemotherapy treatments. It is hoped that future studies will delineate better the optimal use of chemotherapy for these tumors.

Original languageEnglish
Pages (from-to)1027-1052
Number of pages26
JournalHematology/Oncology Clinics of North America
Volume15
Issue number6
DOIs
StatePublished - 2001

Fingerprint

Brain Neoplasms
Drug Therapy
Glioma
Investigational Drugs
Oligodendroglioma
Medulloblastoma
Lymphoma
Therapeutics
Survival
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Novel chemotherapeutic approaches to brain tumors. / Dropcho, Edward.

In: Hematology/Oncology Clinics of North America, Vol. 15, No. 6, 2001, p. 1027-1052.

Research output: Contribution to journalArticle

@article{11a208bd835b42d899f0597775e4c4f3,
title = "Novel chemotherapeutic approaches to brain tumors",
abstract = "In reviewing the numerous investigational drug trials for patients with anaplastic gliomas over the past 20 years, it would be fair to say that there have been more than a few disappointments and that the real impact of many of these therapies on patients' duration and quality of survival has been minor at best. It is also fair to state that there has been progress in developing new types of chemotherapy and other agents, in devising new treatment strategies, and in gaining a deeper understanding of the problems that must be overcome to treat patients with anaplastic gliomas successfully. The past several years have seen the realization that oligodendroglioma, primary CNS lymphoma, and medulloblastoma are sensitive to chemotherapy treatments. It is hoped that future studies will delineate better the optimal use of chemotherapy for these tumors.",
author = "Edward Dropcho",
year = "2001",
doi = "10.1016/S0889-8588(05)70266-5",
language = "English",
volume = "15",
pages = "1027--1052",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Novel chemotherapeutic approaches to brain tumors

AU - Dropcho, Edward

PY - 2001

Y1 - 2001

N2 - In reviewing the numerous investigational drug trials for patients with anaplastic gliomas over the past 20 years, it would be fair to say that there have been more than a few disappointments and that the real impact of many of these therapies on patients' duration and quality of survival has been minor at best. It is also fair to state that there has been progress in developing new types of chemotherapy and other agents, in devising new treatment strategies, and in gaining a deeper understanding of the problems that must be overcome to treat patients with anaplastic gliomas successfully. The past several years have seen the realization that oligodendroglioma, primary CNS lymphoma, and medulloblastoma are sensitive to chemotherapy treatments. It is hoped that future studies will delineate better the optimal use of chemotherapy for these tumors.

AB - In reviewing the numerous investigational drug trials for patients with anaplastic gliomas over the past 20 years, it would be fair to say that there have been more than a few disappointments and that the real impact of many of these therapies on patients' duration and quality of survival has been minor at best. It is also fair to state that there has been progress in developing new types of chemotherapy and other agents, in devising new treatment strategies, and in gaining a deeper understanding of the problems that must be overcome to treat patients with anaplastic gliomas successfully. The past several years have seen the realization that oligodendroglioma, primary CNS lymphoma, and medulloblastoma are sensitive to chemotherapy treatments. It is hoped that future studies will delineate better the optimal use of chemotherapy for these tumors.

UR - http://www.scopus.com/inward/record.url?scp=0035209004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035209004&partnerID=8YFLogxK

U2 - 10.1016/S0889-8588(05)70266-5

DO - 10.1016/S0889-8588(05)70266-5

M3 - Article

C2 - 11770297

AN - SCOPUS:0035209004

VL - 15

SP - 1027

EP - 1052

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 6

ER -